Immix Biopharma Appoints Renowned Biotech Leader And Former Tanox CEO Nancy T. Chang To Board of Directors Following Her Goose Capital Investment

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, has announced that Nancy T. Chang has joined its Board of Directors. Dr. Chang, a highly regarded biotechnology leader and the former CEO of Tanox, Inc., became a board member in connection with her investment as a founding member of Goose Capital.

Dr. Chang is known for her extensive experience in biotechnology innovation and leadership. During her time at Tanox, she and her team invented and developed several groundbreaking therapies, including XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis. These medicines have collectively generated more than five billion dollars in drug sales to date, underscoring her significant impact on advancing life-changing treatments.

Tanox, Inc. was acquired by Genentech/Roche for \$919 million, further demonstrating the company’s value and the importance of its contributions under Dr. Chang’s leadership. EBGLYSS®, one of the key drugs developed under her guidance, is now being commercialized by Eli Lilly and Company.

By bringing Dr. Chang onto its Board of Directors, Immix Biopharma gains the expertise of a proven industry leader with a track record of successfully guiding innovative therapies from development to commercialization. Her experience and strategic insight are expected to strengthen the company’s efforts as it advances its pipeline of cell therapies for patients with life-threatening conditions.